Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Quigley completes phase IIb study of QR-333 in diabetic peripheral neuropathy

Nov. 13, 2008

Raptor reports results from phase IIa study of Convivia in ALDH2 deficiency

Nov. 12, 2008

Sangamo reports results from diabetic neuropathy trial SB-509-601

Nov. 12, 2008

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

Nov. 12, 2008

Novel glutaminyl cyclase inhibitors patented by Probiodrug

Nov. 10, 2008

New agents for gout disclosed in recent Kotobuki patent

Nov. 10, 2008

Plethora reports positive results from phase III efficacy study of PSD-502 for PE

Nov. 10, 2008

ConjuChem presents an update on the clinical development of PC-DAC and PC-Insulin

Nov. 7, 2008

AEGR-733 phase II data demonstrates significant lowering of LDL cholesterol

Nov. 7, 2008

Pfizer discontinues phase III program for CP-945,598 for weight management

Nov. 7, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model
BioWorld Science
Camp4 Therapeutics Corp. has highlighted new preclinical data for CMP-002, the company’s lead investigational antisense oligonucleotide (ASO) therapeutic...